Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Genmab, de Deense parel
Volgen
CAPITAL INCREASE IN GENMAB AS A RESULT OF EXECUTION OF PRIVATE PLACEMENT TO GLAXOSMITHKLINE Copenhagen, Denmark; February 7, 2007 - Genmab A/S (CSE: GEN) hereby announces the direct placement of 4,471,202 ordinary Genmab A/S (the "Company" or "Genmab") shares of DKK 1 nominal value each at a subscription price of DKK 454.65 per share in a private placement (the "Placement") to Glaxo Group Limited "GSK". This Placement which is made in connection with the worldwide agreement to co-develop and commercialize HuMax-CD20 was originally announced on December 19, 2006. Genmab's current share capital amounts to DKK 39,648,355 and will after completion of the capital increase be DKK 44,119,557. It is expected that the new shares will be admitted for listing on the Copenhagen Stock Exchange on February 9, 2007 after registration with the Danish Commerce and Companies Agency. The statutory private placement memorandum prepared in Danish in connection with the Placement has been approved by the Danish Financial Supervisory Authority and published in accordance with applicable rules. www.genmab.com/upload/filing_of_prosp...
Preliminary Annual Report 2006 (February 13, 2007) Letter from the Chief Executive Officer Dear Shareholder, 2006 has been the most exciting year in Genmab’s history. Our key achievements in 2006 included entering a global co-development and commercialization agreement with GlaxoSmithKline (GSK) for HuMax- CD20™ (ofatumumab), initiating three new pivotal studies, reporting positive results in the HuMax-CD20 and HuMax-CD4® (zanolimumab) clinical development programs, developing the UniBody™ technology and completing a private placement of new shares. As a result of this careful execution of our business strategy, we saw a dramatic increase in Genmab’s stock price and market capitalization in 2006. Our stock price increased 181% from DKK 135 (approx. USD 24) on December 31, 2005 to DKK 380 (approx. USD 67) a year later. Our market capitalization also significantly increased by 235% from DKK 4.5 billion (approx. USD 795 million) to DKK 15.07 billion (approx. USD 2.66 billion) in 2006. Building for a Commercial Future Genmab started three new pivotal Phase III clinical studies in 2006: HuMax-CD20 for refractory chronic lymphocytic leukemia (CLL) and rituximab refractory follicular non-Hodgkin’s lymphoma (NHL) and HuMax-EGFr™ (zalutumumab) for refractory head and neck cancer. We also initiated front line combination studies of HuMax-EGFr for head and neck cancer and HuMax-CD20 for CLL. Starting front line studies with these potential cancer products is a new step for Genmab, one that may eventually open up more opportunities for our products in the marketplace. These pivotal and front line studies have the potential to serve as stepping stones on Genmab’s pathway towards a commercial future. We have also continued to make progress in our ongoing development programs. We reported positive results in three HuMax-CD20 studies: Phase I/II rheumatoid arthritis (RA); interim Phase II RA; and Phase I/II CLL duration of response data. In the HuMax-CD4 program with Merck Serono S.A. we announced positive early results in both the Phase III cutaneous T-cell lymphoma (CTCL) and Phase II noncutaneous T-cell lymphoma studies. We received Fast Track status from the US FDA for HuMax-EGFr in refractory head and neck cancer and presented preclinical data showing that HuMax-EGFr appears to be more effective against variations of the EGF receptor than other EGFr directed treatments. We also announced that in pre-clinical studies HuMax-CD38™ was the first antibody shown to inhibit the enzymatic activity of the CD38 molecule. Genmab remains committed to maintaining a broad and diversified product pipeline. With a product portfolio consisting of 38 potential products including 18 preclinical programs and an additional 14 targets under exploration, we are building for the possibility of sustained growth in the future. UniBody - The Next Step in Antibody Development Genmab’s scientific team unveiled the innovative new UniBody technology that has the potential to increase the market for antibody therapeutics. UniBodies are stable, smaller antibody formats which, based on preclinical data, are expected to last longer in the human body than current small antibody formats, lengthening the window of opportunity for a treatment to take effect. We believe this technology has the potential to expand the market for targeted therapeutics especially in disease areas like cancer and inflammation where the small size and special binding characteristics of UniBodies may make them more effective than traditional antibody formats. Genmab is beginning to develop antibody products using the UniBody technology and may consider out-licensing the technology to other companies.www.genmab.com/upload/ifrs_report_200...
Linkje Conference Callwww.vcall.com/conferences/event.asp?I... Slides relevant for the conference call can be found on Genmab’s website www.genmab.com. The conference call will be held in English.
Wederom aankoopmomenten voor Genmab aan 350dkk ! Long in genmab en Crucell . Gr Jo.
De daling van de laatste dagen blijkt tgv verkoop van de 2.5 M aandelen door Medarex. Een derde hiervan schijnt (volgens Bloomberg) bij GS te zijn gekomen. Aangezien de vorige CEO Drakeman weg is, is er verder weinig reden om die aandelen aantehouden. Opvoeren kaspositie voor MEDX is ook aantrekkelijk. De reden van de Genmab koersdaling is dus plausibel. Bijgevolg vandaag weer + 10 DK.. Wellicht koers nu weer verder Up... JMHO
More Biotech Cos Seen Listing On Copenhagen Bourse In 07Last update: 2/19/2007 7:34:53 AMSTOCKHOLM (Dow Jones)--The success of Danish biotechnology companies is expected to encourage more companies in the sector to list on the Copenhagen Stock Exchange in 2007, market watchers say. Jens Peter Toft, global head of corporate finance at Danske Bank, says he expects that 2007 will see healthy initial public offering activity in Denmark dominated in number of transactions by biotechnology companies. "The window for IPOs is definitely there right now. There is a good balance between what sellers and buyers want respectively," he says. Companies mentioned as potential IPO candidates include 7TM Pharma, Natimmune, Egalet, Gastrotech Pharma, Symphogen, Santaris, M2 Medical and Millimed. Florian Schoenharting, co-founder and partner of venture capital firm Nordic Biotech, says that of these, 7TM Pharma stands out as the flagship company. "It has first-class investors involved, they are in phase II with their drug for obesity, which is a big indication, and they have done some international deals," he said. Schoenharting added that Gastrotech and Egalet are also interesting as both companies have good, late-stage products and Egalet also has the advantage of being supported by top venture capital firm Index Ventures. Egalet has two products in late-stage research for the treatment of high blood pressure and pain management and Gastrotech has two drugs in phase II research for catabolic disorders and irritable bowel syndrome. The positive sentiment for biotechnology investments in Denmark has been triggered by a number of companies entering lucrative contracts with international pharmaceutical firms. In December, Genmab A/S (GEN.KO) signed a potential $2.1 billion partnership deal with GlaxoSmithKline PLC (GSK) for its blood cancer drug HuMax-CD20, and shortly after, peer ALK-Abello A/S (ALK-B.KO) entered a contract with Schering-Plough Corp. (SGP), worth up to $255 million for the allergy vaccine Grazax. After nearly five years of no listing activity at all, the Copenhagen stock exchange in the past year and a half has seen three initial public offerings in the biotechnology sector. TopoTarget A/S (TOPO.KO) entered the exchange in June 2005 by raising DKK225 million, followed by Curalogic and LifeCycle Pharma A/S (LCP.KO) in 2006, raising DKK201.6 million and DKK556.6 million, respectively. In total, the biotechnology companies on the Copenhagen Stock Exchange now have a market capitalization of as much as DKK38.8 billion ($6.8 billion.) -By Malin Rising, Dow Jones Newswires; +45 33 111 524; malin.rising@dowjones.com (END) Dow Jones NewswiresFebruary 19, 2007 07:34 ET (12:34 GMT)
Medarex Announces Sale of Shares in Genmab A/S Tuesday February 20, 7:00 am ET PRINCETON, N.J., Feb. 20 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) announced today that it has sold approximately 2.5 million shares of Genmab A/S which stock is traded on the Copenhagen Stock Exchange. The trade is expected to settle on February 21, 2007. Medarex expects to receive approximately $150 million (USD) in net proceeds from the sale. The sale of Genmab shares is expected to reduce Medarex's equity ownership in Genmab to approximately 11 percent. Dirk. -------------------------------------------------------------------------------- Source: Medarex, Inc.
deze daling is toch wel vrij pittig (324 DK op dit moment), de daling versnelt. ik houd nu ook de vinger aan de buy-knop
En weer dalen. Het lijkt erop dat er een kop-schouder patroon ontwikkelt? Dan kunnen we terug naar 250....
Edjes1 schreef:
En weer dalen.
Het lijkt erop dat er een kop-schouder patroon ontwikkelt? Dan kunnen we terug naar 250....
Met de daling van vandaag (naar 321) ben ik ook wel overtuigd van een terugkeer richting 250. Ik zit helemaal standby om er vol in te kletsen als die 250 benaderd wordt.
op welke beurs noteert Genmab? Ik vind het enkel terug op frankfurt maar weinig handel. Ik zit bij keytradebank...bedankt!
kopenhagen, kun je via abnamro in beleggen
goedemorgen, ik ben wel nieuw op dit forum maar al langer fan van genmab. Dit fonds kun je gewoon bij SNS-bank internetbeleggen aanschaffen. Je koopt dan op de beurs van Kopenhagen. groeter peter
Stimpy1126 schreef:
op welke beurs noteert Genmab? Ik vind het enkel terug op frankfurt maar weinig handel. Ik zit bij keytradebank...bedankt!
www.genmab.com/InvestorCentre/StockIn...
GENMAB TO PRESENT AT NINTH ANNUAL BEAR STEARNS LONDON HEALTHCARE CONFERENCE Copenhagen, Denmark; February 22, 2007 – Genmab A/S (CSE: GEN) announced today its CEO, Lisa N. Drakeman, Ph.D., will present at the Ninth Annual Bear Stearns London Healthcare Conference on February 27 at 12 Noon local time. The conference is being held at the Four Seasons Hotel, Park Lane in London, United Kingdom. Approximately 150 healthcare investors from Europe and the United States are expected to attend the conference. Dr. Drakeman’s presentation will be accessible via live and archived webcast at Genmab's website www.genmab.com. www.genmab.com/upload/02_bear_stearns... cc.talkpoint.com/BEAR002/022707b_cy/l...
zijn er nog nieuwtjes betreffende genmab? Koers is erg onrustig en wil nog niet echt terug naar 425
Hierbij het laatste nieuws over Genmab. Genmab is present op de grootste wereld conferency van hun beroepsgroep (200 bedrijven) en zal daar weer nieuwe producten presenteren, wil je dit life volgen, dat kan via hun website: www.genmab.com op 21 maart om 10.15. Copenhagen, Denmark; March 19, 2007 - Genmab A/S (CSE: GEN) announced today its CEO, Lisa N. Drakeman, Ph.D., will present at the Lehman Brothers Tenth Annual Global Healthcare Conference in Miami on March 21 at 10:15AM local time. The conference will feature presentations from nearly 200 companies in the biotechnology and pharmaceutical industries. Dr. Drakeman's presentation will be accessible via live and archived webcast at Genmab's website www.genmab.com. Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb(R) platform for the rapid creation and development of human antibodies to virtually any disease target. In addition, Genmab has developed UniBody(TM), a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. Dit zijn de produkten waar Genmab al het alleenrecht voor heeft, dus dat belooft nog wat: Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-CD20(TM); HuMax-TAC(TM); HuMax-HepC(TM), HuMax-CD38(TM); HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S. groetjes peter
Afgelopen vrijdag toch wat stukjes aangeschaft. De potentie van het aandeel is me te groot om links te laten liggen
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
910,59
+0,71%
EUR/USD
1,0771
-0,10%
FTSE 100
8.433,76
+0,63%
Germany40^
18.773,50
+0,47%
Gold spot
2.360,72
0,00%
NY-Nasdaq Composite
16.340,87
-0,03%
Stijgers
Dalers